Pre-earnings brief
Reports
Thu, Nov 5, 2026
Est. EPS
—
Est. revenue
—
Implied move
±9.6%
EPS beat rate
88%
Viatris Inc. (VTRS) is a global healthcare company that develops and manufactures a wide range of pharmaceutical products. With a market cap of $20 billion, it plays a significant role in the healthcare sector, focusing on providing access to medicines and addressing unmet medical needs.
Last quarter
In Q2 2026, Viatris reported an EPS of $0.69, exceeding expectations by 12.20%. However, the stock fell 7.71% the following day, indicating market concerns despite the earnings beat.
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+7.53%
Avg 1-day reaction
+0.19%
Analysts and investors are cautiously optimistic about Viatris's upcoming earnings, given its recent performance but are wary of potential revenue surprises.
Bull case
If Viatris continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to significant downward pressure on the stock.
The print will turn on these.
Q1
What will the EPS be for Q3-2026, and how does it compare to previous quarters?
The EPS figure will be crucial in determining market sentiment and could influence stock performance significantly.
Q2
How does Viatris plan to address any potential revenue challenges?
Understanding management's strategy for revenue growth or stabilization will be key for investors assessing the company's future prospects.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating Viatris's ability to maintain or grow its EPS despite market challenges, as historical performance shows a strong beat rate.
Supporting evidence
Viatris has consistently beaten EPS estimates in recent quarters, with an 88% beat rate.
The options market is pricing a low implied move of 1.14%, suggesting a lack of confidence in significant volatility.
The stock has shown resilience in the face of earnings surprises, often recovering quickly.
Key risk
If the EPS comes in above $0.70, it could challenge the current cautious consensus.
Pre-commit to what would confirm each case.
The market is focused on EPS and revenue growth as indicators of the company's health, making these thresholds critical.
Bull confirmed if
An EPS of $0.70 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.60 would confirm the bear case, raising concerns about profitability.
What the market is pricing for the move.
Implied Move
±1.14%
Historical Avg
±8.7%
The options market is pricing a modest move around the earnings report, suggesting that investors are not anticipating significant volatility.
Options are pricing ±9.6% while VTRS has averaged ±8.7% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.4%
30d HV
22.1%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.4%, with a raw directional average of -0.4% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
93.67%
of float
Insider
0.32%
of float
Holders
1,368
institutions
Top Holders· as of Jun 2026
FMR, LLC
96,662,102 sh · $1.7B
8.42%
482.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Viatris beats expectations, history suggests the stock could rise by around 2.39% on the following day, confirming positive market sentiment.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess their outlook.
Miss
A miss could lead to a decline of approximately 15.21%, reflecting investor disappointment and potential concerns about future performance.
The lines on the call that would change the story.
Blackrock Inc.
86,019,468 sh · $1.5B
7.49%
2.0%
Vanguard Capital Management LLC
76,046,939 sh · $1.3B
6.62%
1.8%
Davis Selected Advisers
75,232,254 sh · $1.3B
6.55%
-3.8%
Price (T.Rowe) Associates Inc
68,214,436 sh · $1.2B
5.94%
3.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.